What is the recommended dose of nifedipine (calcium channel blocker) for a patient with perniosis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 19, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Nifedipine Dosing for Perniosis

For perniosis (chilblains), nifedipine should be dosed at 20-60 mg daily, typically starting at 20 mg and titrating up to 60 mg daily as needed for symptom control, though the evidence for its efficacy is conflicting and it should not be considered first-line therapy.

Evidence Quality and Recommendations

The evidence for nifedipine in perniosis is limited and contradictory:

Dosing Regimen Based on Available Studies

  • Start with 20 mg daily of nifedipine (extended-release formulation preferred) and titrate up to a maximum of 60 mg daily in divided doses based on response 1
  • The original positive trial used doses ranging from 20-60 mg daily, with most patients responding within the therapeutic window 1
  • Treatment duration should be at least 6 weeks to assess efficacy, as lesion clearance may take several weeks 1

Critical Evidence Limitations

The most recent and highest quality study contradicts earlier findings:

  • A 2016 randomized controlled trial found nifedipine 60 mg daily (30 mg twice daily) was NOT superior to placebo for chronic chilblains, showing a nonsignificant difference of only 1.84 mm on visual analogue scale (P = 0.44) 2
  • This directly contradicts the 1989 trial that showed benefit at 20-60 mg daily 1
  • The 2016 study was methodologically rigorous, double-blind, and specifically designed to replicate the earlier positive trial 2

Alternative Considerations

Given the conflicting evidence for oral nifedipine, consider:

  • Topical nitroglycerine 0.2% ointment showed promising results with 18 of 22 patients achieving complete regression within 2 weeks 3
  • Topical therapy avoids systemic side effects while providing local vasodilation 3
  • Calcium channel blockers may actually worsen erythromelalgia (a related condition), and discontinuation has led to symptom resolution in some patients, suggesting caution with this drug class for microvascular disorders 4

Practical Approach

If you choose to trial nifedipine despite mixed evidence:

  • Use extended-release formulation starting at 20 mg once daily 5, 1
  • Titrate by 20 mg increments every 1-2 weeks up to maximum 60 mg daily 1
  • Monitor for hypotension, peripheral edema, dizziness, and flushing which are common side effects 5, 2
  • The 2016 trial showed significantly higher incidence of edema with nifedipine compared to placebo 2
  • Assess response after 6 weeks of therapy at maximum tolerated dose 1, 2
  • If no improvement after 6 weeks at 60 mg daily, discontinue as further benefit is unlikely 2

Important Caveats

  • Avoid immediate-release nifedipine due to risk of precipitous blood pressure drops that could paradoxically worsen digital perfusion 6
  • The maximum FDA-approved dose for extended-release nifedipine is 180 mg daily for other indications, but doses above 60 mg have not been studied for perniosis 5
  • Primary management should focus on cold avoidance, protective clothing (gloves, warm socks), and keeping extremities warm and dry 7

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Nifedipine Dosing and Administration

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Nifedipine Therapy for Acute Digital Ischemia

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Perniosis A Case Report with Literature Review.

Journal of the American Podiatric Medical Association, 2016

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.